<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275115</url>
  </required_header>
  <id_info>
    <org_study_id>18337A</org_study_id>
    <nct_id>NCT04275115</nct_id>
  </id_info>
  <brief_title>Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects</brief_title>
  <official_title>Interventional, Open-label, One-sequence Study to Investigate the Effects of Multiple Doses of Foliglurax on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Caffeine (CYP1A2), Montelukast (CYP2C8), and Midazolam (CYP3A4) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help determine which types of drugs that may interact with
      foliglurax
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the PK of caffeine, montelukast and midazolam following
      multiple doses of foliglurax in healthy subjects. The study is divided into four periods:

        -  Period 1: investigation of the CYP450 probe substrates (caffeine, montelukast,
           midazolam) alone followed by a 2-day washout before start of Period 2.

        -  Period 2: administration of foliglurax for 7 days to reach steady state.

        -  Period 3: administration of the CYP450 probe substrates in combination with foliglurax
           followed by a 7-day washout before start of Period 4.

        -  Period 4: investigation of the effects of foliglurax on the PK of the CYP450 probe
           substrates following washout of foliglurax.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>Day 1 and 11 for midazolam iv and Day 2,12 and 20 for oral cocktail probe substrates</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity for midazolam after iv administration and for all oral cocktail probe substrates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 and 11 for midazolam iv and Day 2,12 and 20 for oral cocktail probe substrates</time_frame>
    <description>Maximum observed plasma concentration of midazolam after iv administration and for all oral cocktail probe substrates</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Foliglurax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Foliglurax, iv midazolam and cocktail of CYP450 probe substrates</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Cocktail</intervention_name>
    <description>Single oral dose of the cocktail probe substrates (caffeine 200 mg, montelukast 10 mg, midazolam 4 mg)</description>
    <arm_group_label>Foliglurax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foliglurax</intervention_name>
    <description>Foliglurax</description>
    <arm_group_label>Foliglurax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam iv</intervention_name>
    <description>Single intravenous (iv) dose of midazolam 0.025 mg/kg</description>
    <arm_group_label>Foliglurax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women with a body mass index (BMI) of ≥ 18.5 and ≤ 30 kg/m2 and a
             minimum body weight of 60 kg for men and 50 kg for women.

          -  Women of child-bearing potential will have a confirmed non-pregnant and non-lactating
             status.

        Exclusion Criteria:

          -  The subject has a regular intake of more than 500 mg of caffeine per day or
             impossibility to stop intake, on holidays for example, without headaches forcing to
             take caffeine again.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

